Article Abstract

Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?

Authors: Dwight H. Owen, Gregory A. Otterson


There are currently four immune checkpoint inhibitors (ICI) approved for the treatment of stage III or stage IV non-small cell lung cancer (NSCLC) in the United States, with dozens more in clinical development. Nivolumab and pembrolizumab are programmed death-1 (PD-1) antibodies, while atezolizumab and durvalumab are antibodies to programmed death ligand-1 (PD-L1) (1-5).